UBS Group’s Palisade Bio PALI Stock Holding History

UBS Group’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Hold	0	–	-$5K	–	9200
2014 Q4	–	Hold	0	–	–	–	8983

Other funds holding PALI

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

UBS Group's PALI Position: Q2 2026 in Review

UBS Group reduced its Palisade Bio (PALI) stake by 37% in Q2 2026, selling an estimated $846K and leaving 737,307 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #5344.

UBS Group first reported a position in PALI in Q4 2019 and has held it in 26 quarters since. The position peaked at $2.04M in Q1 2026. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

UBS Group held 737,307 shares of Palisade Bio worth $1.54M as of Q2 2026.
UBS Group sold 429,644 Palisade Bio shares in Q2 2026, an estimated $846K.
Palisade Bio made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5344 holding.
UBS Group first reported a position in Palisade Bio in Q4 2019 and has held it in 26 quarters since.
UBS Group's Palisade Bio position peaked at $2.04M in Q1 2026.
124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.